Nantahala Capital Management LLC Raises Stock Holdings in Aileron Therapeutics, Inc. (NASDAQ:ALRN)

Nantahala Capital Management LLC boosted its holdings in shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN) by 82.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 464,367 shares of the company’s stock after acquiring an additional 209,367 shares during the quarter. Nantahala Capital Management LLC owned 2.15% of Aileron Therapeutics worth $1,286,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Warberg Asset Management LLC purchased a new position in shares of Aileron Therapeutics during the second quarter worth approximately $86,000. Texas Capital Bank Wealth Management Services Inc lifted its holdings in shares of Aileron Therapeutics by 65.9% in the 1st quarter. Texas Capital Bank Wealth Management Services Inc now owns 26,171 shares of the company’s stock worth $174,000 after buying an additional 10,398 shares during the period. Finally, University of Texas Texas AM Investment Management Co. bought a new position in shares of Aileron Therapeutics during the 2nd quarter worth $4,925,000. Hedge funds and other institutional investors own 90.89% of the company’s stock.

Aileron Therapeutics Price Performance

ALRN stock opened at $3.54 on Tuesday. The company has a market capitalization of $76.52 million, a P/E ratio of -1.11 and a beta of 2.33. The business has a 50-day moving average price of $2.59 and a 200 day moving average price of $3.57. Aileron Therapeutics, Inc. has a 1-year low of $1.01 and a 1-year high of $7.42.

Aileron Therapeutics (NASDAQ:ALRN) last posted its earnings results on Wednesday, August 14th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.20). On average, analysts anticipate that Aileron Therapeutics, Inc. will post -1.41 earnings per share for the current fiscal year.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).